DDInter40 DDInter1628
Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD.
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Alefacept {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bleomycin
Bleomycin {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Alefacept {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Trimetrexate
Trimetrexate {u} (Compound) causes {v} (Side Effect) Pruritus
Pruritus {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Alefacept {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etoposide
Etoposide {u} (Compound) downregulates {v} (Gene) PLK4
PLK4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Alefacept {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bortezomib
Bortezomib {u} (Compound) upregulates {v} (Gene) MAP3K7
MAP3K7 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Alefacept {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etoposide
Etoposide {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Alefacept {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cisplatin
Cisplatin {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Alefacept {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etoposide
Etoposide {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Alefacept {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Amiodarone
Amiodarone {u} (Compound) downregulates {v} (Gene) PRPF4
PRPF4 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Alefacept {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bortezomib
Bortezomib {u} (Compound) upregulates {v} (Gene) SMNDC1
SMNDC1 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Alefacept {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Amiodarone
Amiodarone {u} (Compound) upregulates {v} (Gene) SLC2A6
SLC2A6 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Bleomycin and Bleomycin (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Trimetrexate and Trimetrexate (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Ruxolitinib (Compound)
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide (Compound) downregulates PLK4 (Gene) and PLK4 (Gene) is bound by Ruxolitinib (Compound)
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib (Compound) upregulates MAP3K7 (Gene) and MAP3K7 (Gene) is bound by Ruxolitinib (Compound)
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Ruxolitinib (Compound)
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide (Compound) binds PTGS2 (Gene) and Etoposide (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Ruxolitinib (Compound)
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Amiodarone and Amiodarone (Compound) downregulates PRPF4 (Gene) and PRPF4 (Gene) is upregulated by Ruxolitinib (Compound)
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib (Compound) upregulates SMNDC1 (Gene) and SMNDC1 (Gene) is upregulated by Ruxolitinib (Compound)
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Amiodarone and Amiodarone (Compound) upregulates SLC2A6 (Gene) and SLC2A6 (Gene) is downregulated by Ruxolitinib (Compound)